equated the nausea and vomiting the drugs caused with their effectiveness. Those who gave cisplatin before 5-HT3RI and NK-1 inhibitors were available, using metoclopramide at 100 mg/m 2 every 2 hours for 6 cycles (along with lorazepam and diphenhydramine
Search Results
Integrating Palliative Care Into Comprehensive Cancer Care
Janet L. Abrahm
New Persistent Opioid and Benzodiazepine Use After Curative-Intent Treatment in Patients With Breast Cancer
Mandy R. Sakamoto, Megan Eguchi, Christine M. Azelby, Jennifer R. Diamond, Christine M. Fisher, Virginia F. Borges, Cathy J. Bradley, and Peter Kabos
prescribed adjunct to antiemetic drugs for chemotherapy-related nausea. 18 Few studies have evaluated short- and long-term opioid use in patients with breast cancer and are limited to single treatment modalities or descriptive statistics. Dispensing patterns
Functional Impairment, Symptom Burden, and Clinical Outcomes Among Hospitalized Patients With Advanced Cancer
Daniel E. Lage, Areej El-Jawahri, Charn-Xin Fuh, Richard A. Newcomb, Vicki A. Jackson, David P. Ryan, Joseph A. Greer, Jennifer S. Temel, and Ryan D. Nipp
symptoms, respectively. Both measures are widely used in the oncology setting and considered to be valid and reliable. The self-administered ESAS-r was used to assess patients’ physical symptoms, including nausea, dyspnea, lack of appetite, pain, drowsiness
Combination Therapy of Physical Activity and Dexamethasone for Cancer-Related Fatigue: A Phase II Randomized Double-Blind Controlled Trial
Sriram Yennurajalingam, Vicente Valero, Zhanni Lu, Diane D. Liu, Naifa L. Busaidy, James M. Reuben, Carolina Diaz Fleming, Janet L. Williams, Kenneth R. Hess, Karen Basen-Engquist, and Eduardo Bruera
used to assess 10 symptoms commonly experienced by patients with cancer during the previous 24 hours: pain, fatigue, nausea, depression, anxiety, drowsiness, dyspnea, anorexia, sleep, and feelings of well-being. 13 , 16 , 21 , 22 For the purpose of
Outcomes From a Patient-Centered, Interprofessional, Palliative Consult Team in Oncology
Andrea Feldstain, Barry D. Bultz, Janet de Groot, Amane Abdul-Razzak, Leonie Herx, Lyle Galloway, Srini Chary, and Aynharan Sinnarajah
quarterly over 2 years). Referrals were from oncology or palliative care clinicians for patients experiencing complex cancer symptoms, including physical symptoms (pain, nausea) or psychosocial-spiritual concerns (depression, anxiety, illness adjustment
NCCN Guidelines® Insights: Palliative Care, Version 2.2021
Featured Updates to the NCCN Guidelines
Maria Dans, Jean S. Kutner, Rajiv Agarwal, Justin N. Baker, Jessica R. Bauman, Anna C. Beck, Toby C. Campbell, Elise C. Carey, Amy A. Case, Shalini Dalal, Danielle J. Doberman, Andrew S. Epstein, Leslie Fecher, Joshua Jones, Jennifer Kapo, Richard T. Lee, Elizabeth T. Loggers, Susan McCammon, William Mitchell, Adeboye B. Ogunseitan, Diane G. Portman, Kavitha Ramchandran, Linda Sutton, Jennifer Temel, Melissa L. Teply, Stephanie Y. Terauchi, Jane Thomas, Anne M. Walling, Finly Zachariah, Mary Anne Bergman, Ndiya Ogba, and Mallory Campbell
(pain, nausea, anxiety, depression, shortness of breath, drowsiness, well-being, loss of appetite, and tiredness) in the last weeks of life. 4 Several groups, including the WHO, ASCO, and American Society of Hematology, recommend integrating
Identification and Characterization of Avoidable Hospital Admissions in Patients With Lung Cancer
Eric M. Lander, Xuanyi Li, Li-Ching Huang, Amanda S. Cass, Wade T. Iams, Emily A. Skotte, Jennifer G. Whisenant, Robert A. Ramirez, Sally J. York, Travis J. Osterman, Jennifer A. Lewis, Christine M. Lovly, Yu Shyr, and Leora Horn
hospitalization included cancer-related pain (n=40; 13%), acute hypoxemic respiratory failure (n=39; 12%), failure to thrive (n=39; 12%), altered mental status (n=23; 7%), and nausea or vomiting (n=22; 7%). Based on a multidisciplinary 2-stage review process, 47
Health-Related Quality of Life in Patients With Metastatic Colorectal Cancer Undergoing Systemic Therapy With or Without Maximal Tumor Debulking
Lotte Bakkerus, Laurien M. Buffart, Tineke E. Buffart, Yannick M. Meyer, Barbara M. Zonderhuis, Cornelis J.A. Haasbeek, Kathelijn S. Versteeg, Olaf J.L. Loosveld, Jan Willem B. de Groot, Mathijs P. Hendriks, Cornelis Verhoef, Hendrik M.W. Verheul, and Elske C. Gootjes
investigated using the EORTC Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). 29 , 30 This questionnaire consists of 5 functional scales (physical, social, role, cognitive, and emotional functioning), 3 symptom scales (fatigue, pain, and nausea
Resurrection of PARP Inhibitors in Breast Cancer
Tomas G. Lyons and Mark E. Robson
survival between the 2 groups. No new safety signals were observed. Any-grade nausea and vomiting were increased with olaparib compared with standard chemotherapy (58% vs 35.2%, respectively, and 29.8% vs 15.4%, respectively). Olaparib was associated with
Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience
Seth A. Wander, Hyo S. Han, Mark L. Zangardi, Andrzej Niemierko, Veronica Mariotti, Leslie S.L. Kim, Jing Xi, Apurva Pandey, Siobhan Dunne, Azadeh Nasrazadani, Avinash Kambadakone, Casey Stein, Maxwell R. Lloyd, Megan Yuen, Laura M. Spring, Dejan Juric, Irene Kuter, Ioannis Sanidas, Beverly Moy, Therese Mulvey, Neelima Vidula, Nicholas J. Dyson, Leif W. Ellisen, Steven Isakoff, Nikhil Wagle, Adam Brufsky, Kevin Kalinsky, Cynthia X. Ma, Joyce O’Shaughnessy, and Aditya Bardia
specific event of interest (via the CTCAE version 4.03) was noted if multiple episodes of an adverse effect occurred during the treatment course. Subjective adverse effects, including diarrhea, fatigue, and nausea, were not graded as part of this